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The need for early life immunization 
Neonatal or early infant immunizations are required to give protection from diseases 
caused by pathogens to which exposure occurs in early life. As an example, the median 
age of infants with a respiratory syncytial virus (RSV) infection severe enough to re- 
quire hospitalization is below 3 months of age worldwide. A significant proportion of 
severe arly infections are due either to encapsulated bacteria such as Haemophilus in- 
fluenzae, Streptococcus pneumoniae, or Neisseria meningitidis or to intracellular 
agents such as viruses [RSV, measles virus (MV), rotavirus, herpes simplex viruses, 
cytomegalovirus], certain bacteria (Listeria monocytogenes, salmonella, mycobacte- 
ria) or other microorganisms (Chlamydiae, Ureaplasma). This enhanced susceptibility 
of newborns and infants to specific infectious diseases is due to limitations of both 
their innate and specific immune system. 
Immune responses in early life differ from adult responses 
The impaired function of monocytes/macrophages in newborns has been associated 
with reduced expression of major histocompatibility complex (MHC) class II and co- 
stimulatory molecules, decreased antigen-processing capacity and altered cytokine 
production. Although little is known about he development of human dendritic ells, 
their maturation appears to be slow and their function as antigen-presenting cells 
(APC) is rather poor at birth [10], thus probably contributing to the limitations of the 
induction of specific immune responses. Although natural killer (NK) cells are present 
in significant numbers at birth, their functional activity [reflected by interferon-y (IFN-y) 
production and NK cell-mediated lysis] also remains low for several weeks. It is not 
yet known precisely which part of these limitations reflects the intrinsic immaturity of 
infant NK cells or their impaired activation by cytokines or factors that prevail in the 
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Fig. 1. Schematic representation of the preferential polarization f neonatal CD4 Th2 cell responses. Factors 
contributing to the preferential development of neonatal CD4 Th2 cell responses compared toadult re- 
sponses have been identified atthe level (i) of antigen-presenting cells(APC): decreased antigen processing, 
decreased xpression f major histocompatibility complex class II and co-stimulatory molecules, decreased 
production ofcytokines such as interleukin (IL)-12; (ii) of natural killer (NK) cells: decreased production f
interferon-y (IFN-T) acting both on APC and CD4 T cells; (iii) of CD4 T cells themselves: hyporesponses to 
IL-12, hyperresponses to IL-4, decreased xpression f CD40 ligand. These factors contribute o the prefer- 
ential production of IL-4, IL-5 and IL-10, reflected by enhancement of IgGland IgE antibodies and 
eosinophilia. In contrast, the low production ftumor necrosis factor-c~ (TNF-c0, IFN-y and weak genera- 
tion of CD8 cytotoxic T lymphocytes (CTL) weakens the neonatal capacity o eliminate microorganisms and 
infected cells 
microenvironment at the time of immune response triggering. As an example, reduced 
interleukin (IL)-12 production by activated mononuclear cells could be an important 
factor limiting NK cell activity since exogenous IL-12 was shown to enhance both 
IFN-y and NK lyric activity of cord blood human NK cells up to adult levels [13]. In- 
versely, reduced IFN- 7 production by NK cells probably affects the development of
specific T cell responses, further contributing to the failure to generate the strong cel- 
lular responses required for clearance of intracellular microorganisms. 
Antibody responses can be raised by newborns and infants in response to infectious 
agents or vaccines, although IgG responses are often slower and weaker than those 
elicited later in life. A lower avidity of vaccine-specific antibodies has also been re- 
ported, probably linked to poor T cell-driven affinity maturation of antibodies. This is 
best reflected by the additional doses of vaccines that must be given to fully immunize 
a 2-month-old infant compared to a 2-year-old toddler. Most importantly, responses to 
carbohydrate determinants such as those contained in bacterial capsules or in heavily 
glycosylated viral proteins can not be elicited in infants before 18-24 months of age. 
This does not relate to the capacity of B cells to recognize the antigen, and the basis 
for these impaired responses to carbohydrates - which explain infant susceptibility o
encapsulated bacteria - remain largely unknown. 
In vitro studies of neonatal T cells have indicated a low frequency of T cell precur- 
sors, poor responses to anti-CD2 and anti-CD3 stimulation in absence of anti-CD28 
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co-stimulation, poor B cell help in terms of both cytokine production and CD40 ligand 
expression by activated T cells, and low cytokine production (mainly IL-2 and IFN-7). 
Recently, neonatal T cells have been shown to follow a preferential development into 
IL-4- and IL-5-producing effector cells [8, 28] and to respond to specific cytokines 
such as IL-12 not only by IFN-y but also by IL-4 production [24]. 
Similar observations have been generated in vivo, in murine models of neonatal 
immunization with conventional vaccines. When the capacity of BALB/c mice at dif- 
ferent stages of immunological maturation to respond to a selection of vaccine anti- 
gens and presentation systems was assessed, significant B and T cell responses to vac- 
cine antigens (tetanus and MV peptides, tetanus toxoid, live viral attenuated MV, ca- 
narypox recombinant measles vector or BCG) were obtained already in the 1 st week 
of life. However, these neonatal responses differed qualitatively from adult responses 
by a decreased IgG2a/IgG1 ratio of vaccine-specific antibodies, the secretion of sig- 
nificantly higher IL-5 and lower IFN-? levels by vaccine-specific T cells and an im- 
paired induction of cytotoxic T cell precursors [3]. This was interpreted as reflecting a
biased pattern of Th2 versus Thl responses induced upon early exposure to vaccines, 
and considered to reflect he situation occurring in human infants (Fig. 1). The polar- 
ization of T cells is believed to depend essentially on the APC capacity; antigen pre- 
sentation by APC that do not express adequate levels of co-stimulators i indeed 
known to result in a selective Th2 activation [5]. Thus, the impaired evelopment of
Thl neonatal responses to antigens, which directly contributes to their susceptibility o 
intracellular agents, could reflect defective neonatal APC-T cell interactions. 
Which vaccines are required for immunization i early life? 
The factors which limit infant responses to infectious agents also affect immune re- 
sponses to vaccine antigens and result in an age-dependent immunogenicity of vac- 
cines. Bacterial polysaccharide vaccines are not immunogenic before the age of 18-24 
months, and although protein/conjugate vaccines can be offered already at a few weeks 
of age, their use in young infants requires the administration of additional vaccine 
doses to reach sufficient immunogenicity. Live viral or bacterial vaccines which are 
capable of inducing stronger cellular immune responses than subunit vaccines can of- 
ten not be used in very early life; with a few exceptions, their early use is limited ei- 
ther by the persistence of antibodies of maternal origin or by safety concerns. 
Thus, specific requirements have to be met by vaccines for them to be considered 
for immunization i early life. Candidate vaccines hould induce protective vaccine re- 
sponses against bacterial/viral pathogens to which infants are exposed early in life and 
represent a significant risk of either severe acute disease or persistent infections. These 
antibody/cellular responses hould be inducible at a young age and confer protection 
before age of exposure to these specific microorganisms. Vaccine-induced immune re- 
sponses hould ideally be sufficiently sustained for long-term protection. In addition, 
novel vaccine candidates should avoid the induction of neonatal tolerance and induce 
infant vaccine responses in spite of the persistence of antibodies of maternal origin. Fi- 
nally, specific vaccine safety issues associated with this early age of relative immun- 
odeficiency have to be met. The purpose of this review is to evaluate how DNA vac- 
cines compare to conventional vaccines for their potential use in early life, based on 
the experimental observations generated so far in murine models of immunization. 
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DNA vaccines induce vaccine responses upon neonatal immunization 
Optimal vaccine candidates for early life immunization should be more rapidly pro- 
tective than has been achieved so far with conventional vaccines. This depends on both 
the earliest age at which immune responses can first be triggered and the kinetics of the 
development of such responses. 
Experiments on neonatal DNA immunization have been initiated in mice, and are 
currently being extended to primates. The capacity of vaccines to induce specific re- 
sponses at various stages of the immune maturation was assessed by immunizing mice 
intramuscularly prior to 3 weeks of age or as adults. Conventional nd DNA vaccines 
were selected in view of their potential clinical significance to target potential infant 
pathogens such as measles {attenuated MV, immunodominant peptides of MV hemag- 
glutinin (MV-HA), live recombinant canarypox (ALVAC-HA [26]) or DNA (MV-HA 
DNA [6]) vectors encoding MV-HA} and tetanus {tetanus toxoid (TT), immunodomi- 
nant peptides of TT or DNA plasmid encoding its fragment C (TetC DNA [1])}. 
Antibody responses 
Characteristics of vaccine antibodies induced in both age groups by either conven- 
tional [3] or DNA [14] vaccines are summarized in Table 1. As a rule, conventional 
vaccines resulted in weaker primary antibody responses when used in early life than in 
adult mice, although antibody titers often reached similar antibody titers after admin- 
istration of a booster immunization. In contrast, a single injection of DNA vaccines 
performed in adult or young mice resulted 4 weeks later in similar antibody titers in 
both age groups. These titers were in general lower than those raised in adult mice by 
a single dose of conventional vaccines. Administration of a second DNA immunization 
similarly boosted antibody levels (tenfold) in both age groups. 
Analysis of vaccine-specific antibody isotypes induced by conventional vaccines 
revealed an age-dependent limitation of the induction of IgG2a vaccine-specific anti- 
bodies by neonatal immunization even in situations where similar titers of IgG1 re- 
sponses were induced (Table 1) [3]. This was also true for live vaccines uch as AL- 
VAC-HA. In contrast, similar antibody patterns were induced by early or adult DNA 
immunization, characterized by a preferential IgG2a (MV-HA) or a mixed IgG1/IgG2a 
(TetC DNA) profile of vaccine-specific antibodies [14]. Thus, in contrast to conven- 
tional vaccines, the use of DNA vaccines was capable of inducing adult-like neonatal 
antibody responses, both quantitatively and qualitatively. 
CD4 T cell responses 
Comparison of CD4 T cell responses induced by adult/neonatal immunization with 
conventional vaccines revealed quantitatively similar T cell proliferation but signifi- 
cant qualitative differences (Table 2). The pattern of CD4 responses observed after im- 
munization of 1- to 3-week-old mice with conventional vaccines consisted of a signif- 
icantly higher production of IL-5 by antigen-specific T cells, as compared to cells from 
adult primed mice [3, 4]. This neonatal burst of IL-5 was mostly observed after neona- 
tal immunization with alum-adsorbed Subunit vaccines. It also occurred, however, 
upon immunization with live viral vaccines (live attenuated MV or ALVAC-HA), 
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Vaccine types Vaccines Vaccine responses Serum antibody titers (ELISA-logl0) 
Adult priming Neonatal priming 
IgG IgG2a IgG IgG2a 
Measles 
Peptide MVH4972 Primary 2.2 < 1.6 1.7 < 1.6 
MVH4972 Secondary 3.8 1.8 1.9" < 1.6 
Atten. virus MVSchwartz Primary 5.5 4.0 4.7* 2.3* 
MVSchwartz Secondary 6.8 4.2 6.8 2.3* 
Avipo× vect. ALVAC-HA Primary 5.4 4.2 4.3* 2.1 * 
ALVAC-HA Secondary 6.3 4.7 6.4 2.3* 
DNA vacc. MV-HA DNA Primary 4.2 3.0 4.1 3.3 
MV-HA DNA Secondary 5.1 3.3 5.2 3.6 
Tetanus 
Peptide TTP30 Primary 3.7 < 1.6 2.5* < 1.6 
TTP30 Secondary 5.5 3.5 5.1 1.8" 
Protein TT Primary 6.3 4.2 5.2" 2.9* 
TT Secondary 7.2 5.0 6.6 3.4* 
DNA vacc. TetC DNA Primary 4.3 3.9 4.2 3.6 
aAntibody titers to measles virus hemagglutinin (MV-HA) or tetanus toxoid (TT) were measured by an en- 
zyme-linked immunosorbent assay (ELISA) as described [3]. Analyses were performed in the serum after one 
or two immunizations ofBALB/c mice primed either as adults or at 1 week of age with the following peptide 
(MVH4972:100 gg in ALOH; TTP30:100 gg in ALOH), protein (TT: 3 gg in ALOH), viral (MVSchwartz: 5x 
106 CCID50 in ALOH; ALVAC-HA: 5 × 107 pfu) or DNA (MV-HA DNA: 100 gg; TetC DNA: 100 gg) vaccines 
* P < 0.05 between adult and neonatal responses, Wilcoxon rank test 
which furthermore failed to induce in young mice adult levels of IFN-y production by 
antigen-specif ic T cells. 
These experiments, as well  as those reported by others [9, 18, 19, 25], indicated 
that the impairment of neonatal cellular responses could derive from a preferential po- 
larization of  neonatal CD4 T cells towards a Th2 rather than a Th l  pattern, as reflected 
by the generation of antibodies of  different isotypes (preferential IgG1 and IgE vs. 
IgG2a antibodies), by a low secretion of I FN- ' /and by an excess of IL-5 production by 
antigen-specif ic CD4 T cells. Although the distinction between Th l /Th2  subsets is less 
stringent in humans, a tendency towards preferential Th2 development of neonatal re- 
sponses has also been observed in a few studies involving human cells [8, 28]. It could 
account for the age-dependent clinical pattern of infectious diseases uch as hepatitis, 
mononucleosis or toxoplasmosis in which symptoms are bel ieved to be essentially im- 
mune mediated and which remain mostly asymptomatic in young children compared 
to adults. It would also explain the lower immunogenic i ty and higher frequency of 
complications fol lowing BCG immunizat ion performed at birth rather than at a few 
months of  age [11, 16]. Finally, it could be l inked to the preferential induction of  al- 
lergic reactions upon early exposure to environmental  ntigens. 
The capacity of  DNA vaccines to induce strong Th l  cellular responses in adult an- 
imals suggested that this novel  antigen-presentation system could represent an inter- 
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Table 2. Antigen-specific cytokine production by T cells induced by conventional and DNA vaccines a 
Vaccine types Vaccines Vaccine 
responses 
Antibody-specifc cytokines 
IFN- 7 IL-5 
Adult Neonatal Adult Neonatal 
Measles 
Peptide MVH4972 Primary < 20 < 20 383 1310" 
Atten. v i rus  MVSchwartz Primary 230 100" 500 2150" 
Avipox vect. ALVAC-HA Primary 150 52* < 150 925* 
DNA vacc. MV-HA DNA Primary 182 315 < 150 < 150 
Tetanus 
Peptide TTP30 Primary < 20 < 20 < 150 800* 
Protein TT Primary < 20 < 20 < 150 1305* 
DNA vacc. TetC DNA Primary 170 95 400 603 
a Cytokine production by antigen-specific T cells was measured byELISA as described [3] in the supematant 
of splenocytes after in vitro restimulation with MV or TT. Analyses wereperformed after a single immu- 
nization of BALB/c mice primed either as adults or at 1 week of age with the following peptide (MVH4972: 
100 btg in ALOH; TTP30:100 gg in ALOH), protein (TT: 3 btg in ALOH), viral (MVSchwartz: 5x 106 
CCID50 in ALOH; ALVAC-HA: 5 x 107 pfu) or DNA (MV-HA DNA: 100 btg; TetC DNA: 100 btg) vaccines 
* P < 0.05 between adult and neonatal responses, Wilcoxon rank test 
esting vaccine strategy for neonatal immunization against intracellular agents. When 
CD4 T cell responses were assessed in mice immunized with DNA vaccines either as 
adults or at 1 week of age [14], similar levels of antigen-specific T cell proliferation 
were observed. Importantly, the cytokine profiles of in vitro-restimulated splenocytes 
were similar in both age groups (Table 2). Depending on the antigen, either a prefer- 
ential secretion of IFN-7 (MV-HA) or mixed IFN- 7 and IL-5 production (tetanus frag- 
ment C) was observed after DNA immunization. These patterns were directly associ- 
ated with either the preferential IgG2a or the mixed IgG1/IgG2a profile of vaccine-spe- 
cific antibodies, respectively. They demonstrate he induction of Th0/Thl responses 
upon neonatal DNA immunization. This property of DNA vaccines to induce strong 
Thl responses in early life appears quite unique: it is apparently only shared with low 
doses of live replicating viral agents ([19] and unpublished observations) and suggests 
the existence of specific requirements for complete activation of neonatal versus adult 
Th 1 responses. Our working hypothesis that activation of neonatal dendritic ells re- 
quires a prolonged exposure to antigen, a feature shared by both DNA and live repli- 
cating infectious agents or vaccines, to fully trigger NK cell and Thl responses. 
CD8 cytotoxic responses 
Among conventional vaccines, only live viruses are capable of raising significant cy- 
totoxic T lymphocyte (CTL) responses in immunologically mature animals or humans. 
However, these responses are weakly induced by neonatal immunization. As an exam- 
ple, adult-like murine CTL responses can not be induced before the age of 3 weeks 
even with live vaccines uch as ALVAC-HA, which raise very strong CTL responses 
in adult animals: a greater than tenfold reduction of the frequency of CTL precursors 
Immunization with DNA vaccines inearly life 239 
(CTLp) was observed upon immunization of 1- to 3-week-old versus adult-primed an- 
imals [3]. Although CTL can be induced in infants by infectious agents uch as HIV or 
RSV, the limited generation of CTL responses in very early life is considered to par- 
ticipate in the impaired clearance of intracellular microorganisms. Furthermore, 
neonatal use of live vaccines is limited by both the relative physiological immunode- 
ficiency and the presence of antibodies of maternal origin which limit the in vivo repli- 
cation required by attenuated vaccines to reach sufficient immunogenicity. 
DNA vaccines have emerged as potent inducers of CD8 cytotoxic responses in adult 
animals. This was found to be also the case upon neonatal DNA immunization. In con- 
trast to the limited induction of neonatal CTL by ALVAC-HA, we observed the induc- 
tion of adult-like CTL responses (assessed by similar frequency of CTLp in spleens) in 
BALB/c mice vaccinated either in the neonatal period or as adults with MV-HA DNA 
[14]. The same observation was made in C57BL/6 mice immunized either as adults or 
in the first weeks of life with a DNA plasmid encoding the nucleoprotein of another 
paramyxovirus, the Sendai virus [14]. Successful induction of CTL by DNA immu- 
nization was reported by Sarzotti et al. [20] in yet another mouse strain: 2-day-old 
NFS/N mice raised a protective CD8-mediated CTL response upon intramuscular im- 
munization with a DNA plasmid encoding the full-length genome of a neuropatho- 
genic retrovirus (Cas-Br-M murine leukemia virus). Thus, the generic property of 
DNA vaccines to induce strong CTL responses, which has been linked to the presence 
in bacterial DNA of specific unmethylated CpG motives capable of rapidly enhancing 
transcription of IL-6, IFN-o~, IFN- 7 and IL-12 in APC [2, 12, 21], is also effective in 
newborns. Through their adjuvant properties, DNA vaccines can fully activate neona- 
tal dendritic cells, sharing only with live replicating agents the capacity to induce the 
adult-like neonatal CD8 responses required for clearance of intracellular microorgan- 
isms. 
How rapidly do immune responses to neonatal DNA immunization develop? 
In these murine models of neonatal immunization involving several mouse strains, 
plasmid vectors and antigens, a single DNA immunization performed in early life was 
capable of generating adult-like vaccine responses even in situations where conven- 
tional vaccines with the corresponding antigens failed to do so. However, the kinetics 
of vaccine response induced by DNA immunization was rather slow (2-6 weeks) in 
both adult and neonatally primed animals. This slow induction affected antibody re- 
sponses, contrasting with the more rapid induction (1-2 weeks) of responses by corre- 
sponding conventional vaccines. Similarly, CTL induction was only detected in all 
mice at 8 weeks post DNA immunization [20], although occurring earlier (4-5 weeks) 
in some animals. This rather slow kinetic of DNA-induced vaccine responses appears 
as a generic property of DNA immunization which could represent a disadvantage for 
the induction of early infant protection. This is especially important in view of the dif- 
ficulty in reverting neonatally induced Th2 responses towards Thl responses. This 
could not be achieved either by Thl-driving adjuvants [4] or by DNA immunization 
[14] given at adult age after neonatal priming with conventional vaccines. 
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Does neonatal DNA immunization carry the risk 
of inducing tolerance rather than immunity? 
Neonatal exposure to antigen under specific conditions has been shown in various ro- 
dent models to induce tolerance rather than immunity to the specific antigen. This was 
shown to depend on several factors uch as the nature and dose of antigen and the tim- 
ing of exposure, which usually has to occur within the first 24 h of life. Contradictory 
reports on the risk of inducing neonatal tolerance by DNA immunization have been 
generated to date. When newborn BALB/c mice were immunized once within their 
first 24 h of life with MV-HA DNA, we observed the induction of strong immune re- 
sponses characterized by similar antibody titers, IFN-3 r production and high frequency 
of CTLp as compared to 1-week-old or adult-primed mice. In another model, a single 
immunization of newborn C3H/He mice with a plasmid vector expressing the rabies 
virus glycoprotein was capable of raising significant antibody responses [29]. Neona- 
tal priming was confirmed by booster administration, and antibody isotypes and cy- 
tokine production were reported as similar to those observed after adult immunization. 
In contrast o these results, a DNA vaccine encoding the circumsporozoite protein 
(CSP) of the Plasmodium yoelii malaria parasite was described as inducing long-last- 
ing tolerance in 2-day- to 1-week-old mice who failed to raise immune responses upon 
adult boosting with DNA [15]. The mechanisms underlying this described tolerance 
induction are uncertain. They could be linked to unique properties of this CSP-DNA 
construct, which mainly induces Th2 rather than Th0/Thl responses in adult mice [22] 
and whose immunogenicity clearly differs from the native CSP protein in terms of 
antigenic determinants [15]. Until further information is available, the induction of im- 
mune tolerance by DNA immunization of newborn mice with certain DNA plasmids 
can thus not be excluded. The importance of this specific observation might, however, 
not be directly relevant o human infant immunization, since the maturation of their 
immune system at birth is such that tolerance induction has not yet been induced by 
postnatal exposure to any antigen. Thus, neonatal DNA immunization appears worth 
assessing in conditions where induction of early immune responses are desired. 
Can sustained vaccine responses be induced by neonatal DNA immunization? 
Infant immunization against hepatitis B would be of little interest if protection waned 
before adolescence and its risk of exposure through sexual transmission. Waning of 
immunity in the absence of a booster is commonly observed with conventional vac- 
cines such as inactivated or subunit vaccines, and there is little evidence yet that even 
live attenuated vaccines would provide life-long immunity in the absence of a repeat 
exposure to wild-type infectious agents. Interestingly, a single DNA immunization was 
shown in adult mice to induce long-lasting responses and life-long maintenance of 
memory cells to various antigens. Prolonged immune responses are similarly observed 
after neonatal DNA immunization [7, 27], and this could represent a significant ad- 
vantage of DNA vaccines over conventional vaccines. However, experiments per- 
formed in non-human adult primates are now showing transient immune responses 
which suggest that this feature could be essentially a characteristic of rodent responses 
to DNA immunization. A weak and transient production of antibodies was also ob- 
served in a first study assessing DNA immunization of newborn chimpanzees against 
hepatitis B virus [17]. However, in spite of negative or very low antibody titers, the 
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tWO animals were protected from a viral challenge performed at 33 weeks, suggesting 
the successful induction of cell-mediated responses. 
Can vaccine responses be induced by neonatal DNA immunization 
in spite of the persistence of antibodies of maternal origin? 
A number of infectious diseases can be either prevented or attenuated by the passive 
transfer of specific antibodies. Prevention of neonatal infections also relies on 
transplacental transfer of antibodies of maternal origin from mother to child. These an- 
tibodies progressively decline below the protective level, but nevertheless remain ca- 
pable for a period of time of interfering with infant responses to immunization. The 
precise mechanisms responsible for the variable effects of maternal antibodies on in- 
fant responses have not yet been fully deciphered. It is known, however, that live at- 
tenuated vaccines have the greatest susceptibility to the inhibitory influence of mater- 
nal antibodies: by neutralizing part of the vaccine inoculum prior to viral entrance 
within host cells, antibodies interfere with the replication cycle in vivo that it requires 
to induce protective responses. This is of significant clinical importance for measles 
immunization i countries where vaccine coverage is not yet sufficient o limit the risk 
of contracting measles prior to the age at which maternal antibodies have sufficiently 
declined in most infants to allow successful immunization [23]. 
To assess the influence of MV-specific maternal antibodies on neonatal responses 
to conventional or DNA vaccines expressing measles hemagglutinin, 2-week-old mice 
born of nonimmune mothers were passively transferred various concentrations of syn- 
geneic immune serum raised by two immunizations with live attenuated measles vac- 
cine. They were immunized 2 days later with either live attenuated measles vaccine, 
live recombinant ALVAC-HA or MV-HA DNA, and followed at regular intervals for 
determination of HA-specific antibodies. When immunization was performed in pres- 
ence of HA-specific antibodies at titers corresponding tothose observed in pups of im- 
mune mothers (> 4.5 log1°), neither of the live vaccines nor DNA was capable of in- 
ducing HA-specific antibodies in the pups (manuscript in preparation). When concen- 
trations of passively transferred antibodies were tenfold lower at time of immuniza- 
tion, both conventional nd DNA vaccines were capable of inducing infant antibody 
responses. Thus, DNA vaccines could be reported either as capable or not of circum- 
venting the inhibitory influence of maternal antibody, depending on the antibody titers 
present at time of immunization. This suggests that passive antibodies bind to a frac- 
tion of the antigen expressed by transfected muscle cells which is sufficient, or not, to 
prevent he induction of antibody responses. In this model of measles immunization, 
DNA vaccines, therefore, did not show any advantage over live conventional vaccines 
for infant immunization i the presence of passively transferred antibodies. 
Does neonatal DNA immunization have to meet specific safety issues? 
Ongoing human trials of DNA immunization suggest that these vaccines have no im- 
mediate or early side effects. However, nothing is known yet on the potential long- 
term consequences of such vaccines. The issues of prolonged antigen expression being 
potentially capable of triggering physiopathological immune responses and the ques- 
tions of potential genomic integration will have to be specifically addressed in neona- 
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tal models of immunization, bearing in mind the ongoing maturation of the immune 
system and the high mitotic rates existing in infants. 
Conclusion 
DNA vaccines favorably compare to conventional vaccines in their unique capacity to 
induce, in murine models, adult-like antibody, Thl and CTL responses at a time of yet 
significant immune immaturity. Immune responses to DNA vaccines are, however, sig- 
nificantly slower than the one induced by adjuvanted subunit or live vaccines. Al- 
though they persist for life in mice, preliminary data in non-human adult primates ug- 
gest that this could not be the case in higher mammals. The issue of potential tolerance 
induction will likely not emerge as a critical feature of human neonatal DNA immu- 
nization. However, DNA vaccines are unlikely to prove superior to conventional vac- 
cines in their capacity to circumvent the inhibitory influence of maternal antibodies. 
Thus, the greater perspectives for neonatal DNA immunization could be found in 
models where the induction of Thl and CTL responses are of utmost importance. 
These are essentially infections with intracellular agents responsible for severe/persis- 
tent infections upon early exposure and for which no current efficient and safe con- 
ventional vaccine exists. Evaluating neonatal DNA immunization strategies against 
RSV or herpes viruses, tuberculosis or Chlamydiae therefore merge as sound priori- 
ties. 
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